Noticias Grupo Grünenthal

Bienvenido a la sección de Prensa del Grupo Grünenthal

22 ene 2019

Fabian Raschke Appointed Chief Financial Officer (CFO)

Aachen, Germany, 22 January 2019 – Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s Finance and IT organisation on 1 February 2019. Fabian currently leads Grünenthal’s Group Controlling and manages over 150 employees, including Finance staff in the affiliates.

Ampliar información ...

14 nov 2018

Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US

Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics

Ampliar información ...

30 oct 2018

Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo

Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium.

Ampliar información ...

23 abr 2018

Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)

Aachen, Germany, 23 April 2018 – Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s research and development organization on 1 July 2018. Currently, Philip holds the role of Global Head of Diabetes Research and Translational Medicine and Chief Scientific Officer at Sanofi’s German Hub in Frankfurt.

Ampliar información ...

23 ene 2018

Grünenthal to distribute, promote, and sell MSD’s Women’s Health products in several countries in Latin America

Aachen, January 23, 2018 – Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for distributing, promoting and selling MSD’s Women’s Health products in Brazil, Central America, Colombia, Mexico and Peru. The portfolio comprises several Women’s Health products, including Zoely®, Nuvaring®, Cerazette® and Livial®. MSD will continue to commercialize Nexplanon®/Implanon NXT® throughout that region.

Ampliar información ...

01 sep 2017

Mark Fladrich takes office as the new CCO of the Grünenthal Group

Aachen, Germany, September 1, 2017. The Grünenthal Group today announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO). Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca.

Ampliar información ...

04 oct 2016

Gabriel Baertschi takes office as new CEO of Grünenthal Group
as of October 1, 2016

The Grünenthal Group today announces that Gabriel Baertschi has taken office as new CEO of the Grünenthal Group, an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. The company’s Supervisory Board had named Gabriel Baertschi to become Grünenthal’s new CEO in June 2016. Gabriel Baertschi is joining Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where in his last appointment he served as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques who retires at the end of 2016 after 23 years at Grünenthal.

Ampliar información ...

07 jun 2016

Grünenthal appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer effective October 1, 2016

Swiss native Gabriel Baertschi follows Prof. Dr. Eric-Paul Pâques who retires after 23 years with the company

Grünenthal Group today announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016. Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group. Grünenthal is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany with affiliates in Europe, Latin America and the U.S. In 2015, Grünenthal achieved revenues of € 1.2 bn.

Ampliar información ...

12 jun 2015

Grünenthal, Boston Children’s Hospital and Proteus S.A. announce a partnership and development program for neosaxitoxin

  • Partnership program with Proteus S.A. (Chile) and Boston Children’s Hospital (USA)
  • Grünenthal’s Innovative Medicines Unit driving the program in a new approach to research & development

Ampliar información ...

27 dic 2013

Grünenthal completes acquisition of Empresas Andrómaco

Aachen / Santiago de Chile, December 27, 2013. The Grünenthal Group today announced the acceptance of the public tender offer with respect to the acquisition of all issued and outstanding shares of Laboratorios Andrómaco S.A. Inversiones Gruchi Limitada, a subsidiary of Grünenthal GmbH, Germany, has acquired 81.59% of all issued and outstanding shares of Laboratorios Andrómaco S.A. through a public tender offer.

Ampliar información ...

Siguientes [6]